Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 7, 2011, Pages 1111-1125

  Smith, Howard S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Abuse; chronic pain; morphine; opioid

Indexed keywords

MORPHINE SULFATE; MORPHINE SULFATE PLUS NALTREXONE; PLACEBO;

ANXIETY; ARTICLE; BACTERIAL ARTHRITIS; BASAL CELL CARCINOMA; BIOEQUIVALENCE; CHOLELITHIASIS; CHRONIC PAIN; COLITIS; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSURIA; ENTEROPATHY; FATIGUE; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; INTESTINAL BLOCKAGE; KIDNEY CARCINOMA; LUNG CANCER; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; NAUSEA; OSTEOARTHRITIS; PANCREATITIS; PHARMACODYNAMICS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRAL GASTROENTERITIS; VOMITING; XEROSTOMIA;

ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; EUPHORIA; FEMALE; HUMANS; MALE; MORPHINE; NALTREXONE; PAIN;

EID: 79953893278     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.571205     Document Type: Article

References (67)

1. Chou R, Fanciullo GJ, Fine PG, et al. Opioid treatment guidelines. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
2. Coluzzi F, Pappagallo M. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol 2005;71:425-33 (Pubitemid 43932967)
3. Cherny NI. Opioid analgesics: comparative features and prescribing guidelines. Drugs 1996;51:713-37
4. Atluri S, Boswell M, Hansen H, et al. Guidelines for the use of controlled substances in the management of chronic pain. Pain Physician 2003;6:233-57 (Pubitemid 36974918)
5. American Society of Anesthesiologists Task Force and American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management, an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology 2010;112:810-33
6. Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). World Inst Pain 2008;8:287-313
7. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349:1943-53 (Pubitemid 37409712)
8. Schneider JP, Kirsh KL. Defining clinical issues around tolerance, hyperalgesia, and addiction: a quantitative and qualitative outcome study of long-term opioid dosing in a chronic pain practice. J Opioid Manag 2010;6:385-95
9. American Academy of Pain Medicine/American Pain Society. The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and American Pain Society 1996. Available from: http://www. ampainsoc.org/advocacy/opioids.htm [Last accessed 8 October 2010]
10. Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 2007;297:249-51 (Pubitemid 46143290)
11. Kuehn BM. Scientists probe ways to curb opioid abuse without hindering pain treatment. JAMA 2007;297:1965-7 (Pubitemid 46740365)
12. Katz NP, Adams EH, Benneyan JC, et al. Foundations of opioid risk management. Clin J Pain 2007;23:103-18 (Pubitemid 46145457)
13. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume 1. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHA Publication No. SMA 10-4586 Findings), 2010. Available from: http://www.oas.samhsa.gov/NSDUH/ 2k9NSDUH/2k9ResultsP.pdf [Last accessed 8 October 2010]
14. FDA Consumer Health Information. Combating misuse and abuse of prescription drugs. FDA Consumer Health Information/US Food and Drug Administration. July 2010. Available from: http://www.fda.gov/downloads/ ForConsumers/ConsumerUpdates/UCM220434.pdf [Last accessed 8 October 2010]
15. US Department of Health and Human Services. Emergency department visits involving nonmedical use of selected prescription drugs-United States, 2004-2008. Morb Mortal Wkly Rep 2010;59:705-14
16. Office of National Drug Control Policy Executive Office of the President. Prescription for danger: a report on the troubling trend of prescription and over-the-counter drug abuse among the nation's teens. Office of National Drug Control Policy, Executive Office of the President website. January 2008. Available from: http://www.theantidrug. com/pdfs/prescription-report.pdf [Last accessed 4 May 2009]
17. McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav 2007;32:562-75 (Pubitemid 46038570)
18. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc 2009;84:593-601
19. US Food and Drug Administration. Outpatient prescription opioid utilization in the US, years 2000-2009. Available from: http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AnestheticAndLifeSupportDrugsAdvisory Committee/UCM220950.pdf [Last accessed 14 February 2011]
20. RADARS system data indicate immediate release opioids responsible for higher proportion of misuse, abuse and diversion than extended release opioids. RADARS Syst News 2009;4(2). Available from: http://www.radars.org/LinkClick. aspx?fileticket=PEUldFIeRps% 3D&tabid=1114 [Last accessed 28 March 2011]
21. Sloan P, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv 2006;3:489-97
22. Paulozzi LJ. Trends in unintentional drug overdose deaths. US Department of Health and Human Services Testimony before Senate Judiciary Subcommittee on Crime and Drugs. 12 March 2008. Available from: http://www.hhs.gov/asl/testify/ 2008/03/t20080312b.html [Last accessed 19 May 2010]
23. Fudala PJ, Johnson RE. Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 2006;83(Suppl 1):S40-7
24. Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs 2009;18:255-63
25. Griffiths RR, Bigelow GE, Ator NA. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend 2003;70:S41-54 (Pubitemid 36577514)
26. Stauffer J, Setnik B, Sokolowska M, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 2009;29:777-90
27. Johnson FK, Stark JG, Bieberdorf FA, Stauffer J. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. Clin Ther 2010;32:1149-64
28. ReVia [package insert]. Noble Park, Victoria, Australia: Bristol-Myers Squibb Australia Pty Ltd, July 2002
29. Johnson FK, Ciric S, Boudriau S, et al. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA) and an extended release morphine sulfate capsule formulation (KADIAN) in healthy adults under fasting conditions. Am J Ther 2011;18:2-8
30. Katz N, Sun S, Johnson F, Stauffer J. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain 2010;11:303-11
31. Johnson F, Ciric S, Boudriau S, et al. Food efffects on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. Adv Ther 2010;27:846-58
32. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits (Office of Applied Studies, DAWN Series D-30, DHHS Publication No. SMA 08-4339), 2008. Available from: http://dawninfo.samhsa. gov/files/ED2006/ DAWN2k6ED.pdf [Last accessed 22 April 2009]
33. Johnson FK, Ciric S, Boudriau S, et al. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. J Clin Pharmacol; In press
34. Cole JO, Orzack MH, Beake B, et al. Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry 1982;43:69-74
35. Martin WR, Sloan JW, Sapira JD, Jasinski DR Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971;12:245-58
36. Webster L, Jones JB, Johnson F, et al. Relative drug-liking/euphoria effects of intravenous morphine alone and in combination with naltrexone in recreational opioid users. Poster presented at the International Association for the Study of Pain 12th World Congress on Pain, Glasgow, Scotland, UK, 17 August 2008
37. Katz N, Hale M, Morris D, Stauffer J. Morphine sulfate and naltrexone hydrochloride extended-release capsules in patients with chronic osteoarthritis pain. Postgrad Med 2010;122:112-28
38. Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 2007;23:117-28 (Pubitemid 46191677)
39. Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo-and active-controlled phase III study. J Pain 2005;6:21-8 (Pubitemid 40051998)
40. Webster LR, Brewer R, Wang C, et al. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J Pain Symptom Manage 2010;40:734-46
41. Wallace M, Moulin DE, Rauck RL, et al. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. J Opioid Manag 2009;5:97-105
42. Portenoy RK, Farrar JT, Backonja MM, et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain 2007;23:287-99 (Pubitemid 46650020)
43. Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 2000;160:853-60 (Pubitemid 30165247)
44. Nicholson B, Ross E, Sasaki J, Weil A. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Curr Med Res Opin 2006;22:1503-14 (Pubitemid 44297429)
45. Milligan K, Lanteri-Minet M, Borchert K, et al. Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic non-cancer pain. J Pain 2001;2:197-204 (Pubitemid 32776971)
46. Dellemijn PL, van Duijn H, Vanneste JA. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 1998;16:220-9 (Pubitemid 28478235)
47. Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002;23:278-91 (Pubitemid 34462941)
48. Allan LG, Rucharz U, Simpson K, Slappendel R Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine 2005;30:2484-90 (Pubitemid 41669082)
49. Johnson F, Manning D, Wang C, Stauffer J. Evaluation of naltrexone concentrations following dosing with ALO-01 (morphine sulfate and naltrexone hydrochloride) extended release capsules for 1 year in patients with chronic pain. Poster presented at the 71st Annual Meeting of The College on Problems of Drug Dependence, Reno, NV, USA, 20-25 June 2009
50. Meyer MC, Straughn AB, Lo MW, et al. Bioequivalence, dose- proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry 1984;45:15-19 (Pubitemid 14030105)
51. Wong DF, Ye W, Zhou Y, et al. In vivo human opiate receptor occupancy of naltrexone: a dose-response analysis. Abstract presented at the 36th Annual Meeting of the Society for Neuroscience, Atlanta, GA, USA, 14-18 October 2006
52. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003;35:253-9 (Pubitemid 36927370)
53. Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987;13:293-308 (Pubitemid 17143298)
54. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002;287:622-7 (Pubitemid 34252015)
55. Ruan X, Chen T, Gudin J, et al. Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag 2010;6:300-3
56. Jang DH, Robe JC, Hoffman RS. Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda). Ann Emerg Med 2010;55:303-4
57. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005;6:107-112 (Pubitemid 40590522)
58. Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007;23:648-60 (Pubitemid 47462170)
59. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 2008;10:11-18
60. Lavine G. Abuse deterrence focus of upcoming opioid formulations. Am J Health Syst Pharm 2008;65:381,385
61. Gershell L, Goater JJ. Making gains in pain. Nat Rev Drug Discov 2006;5:889-90 (Pubitemid 44660601)
62. Brennan MJ, Stanos S. Strategies to optimize pain management with opioids while minimizing risk of abuse. PM R 2010;2:544-58
63. Gourlay DL, Heit HA. Pain and addiction: managing risk through comprehensive care. J Addict Dis 2008;27:23-30
64. Simoni-Wastila L, Tompkins C Balancing diversion control and medical necessity: the case of prescription drugs with abuse potential. Substance Abuse Misuse 2001;36:1275-96
65. Butler SF, Budman SH, Licari A, et al. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf 2008;17:1142-54
66. Cicero TJ, Dart RC, Inciardi JA, et al. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med 2007;8:157-70
67. Department of Health and Human Services. Identification of drug and biological products deemed to have risk evaluation and mitigation strategies for purposes of the Food and Drug Administration Amendments Act of 2007, 2008; Federal Register 73: 16313-4. Available from: http://www.fda. gov/OHRMS/DOCKETS/98fr/E8-6201. pdf [Last accessed 21 February 2011]